1.1Nitrile at the R position
The nitrile projects a narrow, linear group from the scaffold and withdraws electron density from the attachment site. Its terminal nitrogen serves as a hydrogen-bond acceptor.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The nitrile projects a narrow, linear group from the scaffold and withdraws electron density from the attachment site. Its terminal nitrogen serves as a hydrogen-bond acceptor.
The group attaches through an ether oxygen and places a terminal hydroxyl two methylene units away. The ether oxygen accepts hydrogen bonds, and the terminal hydroxyl can donate and accept them.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An inhibitor panel is applied to primary canine fibroblast cultures to measure how PIP4K activity affects cellular phosphoinositide levels. Parallel cultures receive non-targeting small interfering RNA or small interfering RNA directed against one canine PIP4K2 isoform per condition. Lipids from compound-treated and vehicle-treated cultures are quantified by liquid chromatography coupled to mass spectrometry, with chromatographic separation of phosphatidylinositol bisphosphate positional isomers. The change in phosphatidylinositol 4,5-bisphosphate is compared across knockdown conditions and normalized to total cellular protein.
A matched degrader series contains linear linkers with 10, 12, and 14 methylene groups between two fixed terminal amide junctions. The same PIP4K-binding and ubiquitin ligase-binding groups are attached to both ends of each spacer. Cells receive an eight-point, threefold concentration series, and PIP4K abundance is measured at 2, 8, and 24 hours. Intracellular compound concentrations are measured in parallel to compare degradation at matched exposure.
A glass microfluidic chamber holds an adherent cell layer and receives compound-containing medium or vehicle from two reservoirs connected through a switching valve. Cells express a PIP4K isoform with a luminescent peptide tag inserted at its endogenous locus. The valve delivers a compound pulse followed by compound-free medium, and a luminometer records the tagged protein signal during exposure and washout. A parallel vehicle channel supplies the baseline for signal drift, and outlet samples establish when the compound clears the chamber.
An automated liquid handler dispenses degrader candidates into assay plates containing cells with an endogenous PIP4K abundance reporter. Software fits concentration-response curves and records maximum protein loss, the concentration that produces half-maximal loss, and cell viability. A Gaussian process model uses linker length, rotatable bond count, and hydrogen-bond acceptor count to rank candidates from a predefined synthesis list. The next assay batch includes candidates with high predicted protein loss and candidates with high prediction uncertainty.
Ring 3 is oxetan-3-yl and attaches to the scaffold through the carbon opposite the ring oxygen. The four-membered ring holds the ether oxygen two bonds from the attachment carbon along either ring path.
Ring 3 is a phenyl ring bearing a nitrile para to the scaffold attachment. The aromatic ring fixes the nitrile along the axis through the attachment carbon and the opposite ring carbon.
Ring 5 is morpholin-2-yl and attaches through a carbon adjacent to the ring oxygen. The six-membered ring contains an ether oxygen and a secondary amine at opposite positions.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
R4, R5, R6, R10, and R17 are each independently H, halogen, C1-3 alkyl, or C1-3 alkoxy;A · US 2023/0013585 A1 · ¶
R21 is i) H, ii) C3-7 monocyclic or bridged bicyclic cycloalkyl optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, C1-3 alkyl, and C1-3 alkoxy, wherein the C1-3 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, and C1-3 alkoxy, iii) 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, wherein the 4-6 membered monocyclic heterocyclyl is optionally substA · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituentsB · US 2023/0065527 A1 · ¶ 88
R7 is i) H, ii) C1-6 alkyl optionally substituted with 1-3 groups independently selected from —OH, halogen, C1-3 alkoxy, and C3-7 monocyclic cycloalkyl, or iii) C3-7 monocyclic cycloalkyl optionally substituted with 1-3 groups independently selected from —OH, halogen, C1-3 alkyl, and C1-3 alkoxy;A · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituentsB · US 2023/0065527 A1 · ¶ 88
R11 is i) 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, oxo, C1-3 alkyl, and C1-3 alkoxy, ii) —S(O)2C1-6 alkyl, iii) —S(O)2C3-7 monocyclic cycloalkyl, iv) C1-6 alkyl optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, C1-3 alkoxy, and C3-7 monocyclicA · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituentsB · US 2023/0065527 A1 · ¶ 88
A is a pyridinyl, pyridonyl, quinolinyl, or isoquinolinyl, each of which is optionally substituted with 1-4 R9; each R9 is independently i) halogen, ii) C1-6 alkoxy optionally substituted with 1-3 groups independently selected from —OH, halogen, C1-3 alkyl, and C3-7 monocyclic cycloalkyl, iii) —NH2, iv) —NH(C1-6 alkyl), wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, and C1-3 alkoxy, v) —N(C1-6 alkyl)2, wherein each CA · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituentsB · US 2023/0065527 A1 · ¶ 88
or a pharmaceutically acceptable salt thereof, wherein: one of R1 and R2 is H, —CN, —OH, halogen, or C1-6 alkyl, and the other of R1 and R2 is H, halogen, or C1-6 alkyl, wherein each C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH and halogen, or R1 and R2 together with the carbon to which they are attached form a C3-7 monocyclic cycloalkyl or a 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, OA · US 2023/0013585 A1 · ¶
Ring A is selected from the group consisting of: a monocyclic C5-7 cycloalkyl substituted with R2a1; a bicyclic C6-12 cycloalkyl substituted with R2a2; a 5-7 membered nitrogen-containing monocyclic heterocyclyl, wherein a nitrogen of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a3, wherein a carbon of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a4 or R2a5, and wherein when R2a5B · US 2023/0065527 A1 · claim 1
“Lower alkylene groups” are straight-chained —CH2— tethering groups, forming bonds to connect molecular fragments via their terminal carbon atoms. Examples include but are not limited to methylene (—CH2—), ethylene (—CH2CH2—), propylene (—CH2CH2CH2—) and butylene (—CH2CH2CH2CH2—).B · US 2023/0065527 A1 · ¶ 30
A wavy line drawn through a line in a structure indicates a point of attachment of a group.A · US 2023/0013585 A1 · ¶ 102
R21 is i) H, ii) C3-7 monocyclic or bridged bicyclic cycloalkyl optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, C1-3 alkyl, and C1-3 alkoxy, wherein the C1-3 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, and C1-3 alkoxy, iii) 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, wherein the 4-6 membered monocyclic heterocyclyl is optionally substA · US 2023/0013585 A1 · ¶
Rm1 and Rm2 can be independently selected from hydrogen, —C1-4 alkyl, C3-6 monocyclic cycloalkyl, C5-12 bicyclic cycloalkyl, 5- or 6-membered monocyclic heteroaryl, 4-7 membered monocyclic heterocyclyl, 8-11 membered fused-heteroaryl, 8-11 membered fused-heterocyclyl and —Rx2; wherein the monocyclic heteroaryl, the bicyclic heteroaryl the monocyclic heterocyclyl and the bicyclic heterocyclyl contain at least one heteroatom independently selected from O (oxygen), S (sulfur), CB · US 2023/0065527 A1 · ¶ 90
L1 is a cyclobutylene optionally substituted with 1-6 groups independently selected from —OH, halogen, C1-3 alkyl, and C1-3 alkoxy;A · US 2023/0013585 A1 · ¶
An empty cell means only that no passage was reproduced there.
Current therapies utilizing these antibodies are highlighted by both significant and durable response to many different cancers but also by low overall response rates (<25%).A · US 2023/0013585 A1 · ¶ 3
Accordingly, a small molecule inhibitor of HPK1 could provide a novel way to enhance anti-tumor immunity and also provide a way to increase the response to checkpoint receptor blockade.A · US 2023/0013585 A1 · ¶ 4
There is an ongoing need for PD-1/PD-L1 therapies and improvements thereof for the treatment of disease.B · US 2023/0065527 A1 · ¶ 3
Also disclosed herein are pharmaceutical compositions of compounds described herein and uses of or methods of using the compounds for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.B · US 2023/0065527 A1 · ¶ 2
patent.fyi, US 2026/0355196 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355196/, SHA-256 15326369c069d81be8496fc0186c50bad6f331694761eaae3475eb1e17333788